SCHEMBL10162840

SCHEMBL10162840

Cc1ccc(CNC(=O)c2cc(C(=O)NCc3ccc4oc(=O)n(C)c4c3)nc3ccnn23)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
TP53 P04637 6/20 0.45
LMNA P02545 3/20 0.45
RXFP1 Q9HBX9 1/20 0.45
ALDH1A1 P00352 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KMT2A Q03164 5/20 0.43
POLB P06746 4/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
THRB P10828 2/20 0.40
ADAMTS4 O75173 1/20 0.40
MMP3 P08254 1/20 0.40
MMP8 P22894 1/20 0.40
MMP12 P39900 1/20 0.40
MMP13 P45452 1/20 0.40
MEN1 O00255 3/20 0.40
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162873 0.93 TP53 (0.44) L3MBTL1TP53LMNAALDH1A1NPSR1
SCHEMBL8225360 0.93 LMNA (0.41) L3MBTL1TP53LMNARXFP1ALDH1A1
SCHEMBL10162848 0.92 POLB (0.48) L3MBTL1TP53LMNARXFP1ALDH1A1
SCHEMBL8225958 0.92 TP53 (0.44) L3MBTL1TP53LMNAKMT2APOLB
SCHEMBL10162891 0.92 MMP13 (0.40) L3MBTL1TP53LMNARXFP1ALDH1A1
SCHEMBL10162862 0.91 TP53 (0.40) L3MBTL1TP53LMNARXFP1ALDH1A1
SCHEMBL8227479 0.91 MEN1 (0.44) L3MBTL1TP53KMT2APOLBADAMTS4
SCHEMBL10162888 0.91 MMP13 (0.39) L3MBTL1TP53LMNARXFP1ALDH1A1
SCHEMBL8221129 0.91 TP53 (0.39) L3MBTL1TP53LMNARXFP1ALDH1A1
SCHEMBL10208197 0.91 TP53 (0.39) L3MBTL1TP53LMNARXFP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 L3MBTL1 4566/4885TP53 3627/4885LMNA 2387/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 L3MBTL1 4566/4885TP53 3627/4885LMNA 2387/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 L3MBTL1 4566/4885TP53 3627/4885LMNA 2387/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 L3MBTL1 4566/4885TP53 3627/4885LMNA 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.